Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous HS628 in combination with MTX versus Actemra in combination with MTX, in participants with moderate to severe active rheumatoid arthritis (RA) who have inadequate response to current MTX therapy. The study comprises a 24-week treatment phase, followed by a 4-week safety observation period.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06048224
Study type Interventional
Source Zhejiang Hisun Pharmaceutical Co. Ltd.
Contact
Status Completed
Phase Phase 3
Start date December 28, 2020
Completion date January 31, 2022